Folfirinox
Folfirinox
gemcitabine/nab-paclitaxel
metastatic
pancreatic adenocarcinoma
survival
Journal
Therapeutic advances in gastroenterology
ISSN: 1756-283X
Titre abrégé: Therap Adv Gastroenterol
Pays: England
ID NLM: 101478893
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
05
2019
accepted:
16
08
2019
entrez:
11
10
2019
pubmed:
11
10
2019
medline:
11
10
2019
Statut:
epublish
Résumé
Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-line treatments in patients with metastatic pancreatic cancer (mPC). However, data comparing these two chemotherapeutic regimens and their sequential use remain scarce. Data from two independent cohorts enrolling patients treated with FFX ( In the whole study population, OS was significantly higher in FFX (14 months; 95% CI: 10-21) than in GN groups (9 months; 95% CI: 8-12) before ( This study shows greater OS with FFX than with GN in patients with mPC. GN after FFX failure appears more feasible than the reverse sequence.
Sections du résumé
BACKGROUND
BACKGROUND
Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-line treatments in patients with metastatic pancreatic cancer (mPC). However, data comparing these two chemotherapeutic regimens and their sequential use remain scarce.
METHODS
METHODS
Data from two independent cohorts enrolling patients treated with FFX (
RESULTS
RESULTS
In the whole study population, OS was significantly higher in FFX (14 months; 95% CI: 10-21) than in GN groups (9 months; 95% CI: 8-12) before (
CONCLUSION
CONCLUSIONS
This study shows greater OS with FFX than with GN in patients with mPC. GN after FFX failure appears more feasible than the reverse sequence.
Identifiants
pubmed: 31598136
doi: 10.1177/1756284819878660
pii: 10.1177_1756284819878660
pmc: PMC6764033
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1756284819878660Informations de copyright
© The Author(s), 2019.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Br J Cancer. 2015 Sep 29;113(7):989-95
pubmed: 26372701
J Med Econ. 2017 Apr;20(4):345-352
pubmed: 27919186
BMC Cancer. 2019 May 17;19(1):468
pubmed: 31101022
Pancreas. 2019 Aug;48(7):920-926
pubmed: 31180981
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Adv Ther. 2018 Oct;35(10):1564-1577
pubmed: 30209750
J Clin Oncol. 2009 Nov 20;27(33):5660-9
pubmed: 19858397
Am J Clin Oncol. 2017 Oct;40(5):507-511
pubmed: 25844823
Oncologist. 2019 Jun 4;:null
pubmed: 31164454
Pharmacoeconomics. 2018 Nov;36(11):1333-1343
pubmed: 29981004
Int J Cancer. 2019 Mar 1;144(5):981-990
pubmed: 30006989
Oncologist. 2015 Feb;20(2):143-50
pubmed: 25582141
Pancreatology. 2019 Jan;19(1):97-104
pubmed: 30529068
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Drugs Real World Outcomes. 2018 Sep;5(3):149-159
pubmed: 29946913
Invest New Drugs. 2018 Aug;36(4):732-741
pubmed: 29616439
J Gastrointest Cancer. 2019 Mar;50(1):62-68
pubmed: 29143916
Pancreatology. 2018 Oct;18(7):841-845
pubmed: 30075908
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Cancer Chemother Pharmacol. 2018 Aug;82(2):245-250
pubmed: 29846765
Expert Rev Clin Pharmacol. 2017 Oct;10(10):1153-1160
pubmed: 28795609